Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results

Syndax Pharmaceuticals (NASDAQ:SNDX) posted its quarterly earnings data on Thursday. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.11, Zacks reports. Syndax Pharmaceuticals had a negative net margin of 165.37% and a negative return on equity of 206.62%. The firm’s quarterly revenue was up 224.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.98) earnings per share.

Here are the key takeaways from Syndax Pharmaceuticals’ conference call:

• Combined Q1 sales topped $100 million — Revuforj net revenue was $48.9M (double‑digit QoQ growth) and NICTIMVO net revenue was $55M (Syndax recorded $15.9M collaboration revenue), with both products annualizing near $200M.
• Revuforj is driving higher transplant rates in KMT2A — recent analysis shows nearly 50% of KMT2A patients are proceeding to stem‑cell transplant (up from ~33%), ~45% have restarted therapy post‑transplant so far, and management expects 70–80% long‑term, a dynamic the company calls a short‑term revenue headwind that should lengthen treatment durations and support sustainable growth.
• Frontline revumenib program advancing — global site activation and enrollment are underway in pivotal Phase III trials (EVOLVE‑2, REVEAL) and the RAVEN Phase II, and Syndax expects to be first to report pivotal frontline menin‑inhibitor data with multiple presentations planned at ASCO, EHA and ASH.
• Two potentially transformative axatilimab readouts due in Q4 2026 — topline Phase II data for axatilimab plus ruxolitinib in chronic GVHD and the MAXPIRe IPF trial could materially expand market opportunity if positive, supported by a clear mechanistic rationale and encouraging GVHD lung responses to date.
• Strong cash runway and disciplined expense guidance — $352.1M in cash and marketable securities as of March 31, 2026, and guidance for ~ $400M total R&D+SG&A in 2026 (ex‑$50M non‑cash stock comp), which management says positions the company to continue investing and move toward profitability.

Syndax Pharmaceuticals Stock Up 3.9%

Shares of SNDX stock traded up $0.80 during trading on Thursday, reaching $21.43. The company’s stock had a trading volume of 1,660,342 shares, compared to its average volume of 1,371,331. The business has a fifty day moving average price of $23.03 and a 200-day moving average price of $20.35. The company has a quick ratio of 4.12, a current ratio of 4.40 and a debt-to-equity ratio of 5.32. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -6.51 and a beta of 0.41. Syndax Pharmaceuticals has a one year low of $8.58 and a one year high of $25.59.

Wall Street Analyst Weigh In

Several research firms have weighed in on SNDX. JPMorgan Chase & Co. raised their price objective on shares of Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a research report on Monday, March 9th. Jefferies Financial Group restated a “buy” rating and issued a $40.00 price objective (down from $48.00) on shares of Syndax Pharmaceuticals in a research report on Monday, March 30th. Mizuho lowered their price objective on shares of Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. Wall Street Zen upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Stifel Nicolaus set a $45.00 price objective on shares of Syndax Pharmaceuticals in a research report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 17,159 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $360,853.77. Following the sale, the chief executive officer directly owned 491,690 shares of the company’s stock, valued at approximately $10,340,240.70. This represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Keith A. Goldan sold 3,410 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $71,712.30. Following the sale, the chief financial officer directly owned 140,429 shares in the company, valued at $2,953,221.87. This trade represents a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,063 shares of company stock worth $628,332 over the last ninety days. Insiders own 4.10% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in SNDX. AQR Capital Management LLC raised its position in Syndax Pharmaceuticals by 478.8% during the first quarter. AQR Capital Management LLC now owns 377,444 shares of the company’s stock worth $4,637,000 after acquiring an additional 312,231 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Syndax Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after purchasing an additional 3,094 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Syndax Pharmaceuticals in the first quarter valued at $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Syndax Pharmaceuticals by 18.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company’s stock valued at $2,466,000 after purchasing an additional 30,596 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Syndax Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 84,575 shares of the company’s stock valued at $792,000 after purchasing an additional 3,937 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.